Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Mechanisms underlying differential expression of interleukin-8 in breast cancer cells.
|
15208657 |
2004 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3' untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR.
|
15514971 |
2005 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival.
|
15534087 |
2004 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin.
|
17516992 |
2007 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells.
|
17621625 |
2007 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Association of interleukin-8 (IL-8 or CXCL8) -251T/A and CXCR2 +1208C/T gene polymorphisms with breast cancer.
|
17949231 |
2007 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer.
|
18028768 |
2007 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Quantification of these chemokines in breast tumors showed that samples expressing high CXCL8 also produced elevated levels of CXCL1, CXCL3, and CXCL5, and displayed low content of ERalpha.
|
18045955 |
2007 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients.
|
18689272 |
2006 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo.
|
19109168 |
2009 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells.
|
21390186 |
2011 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Notably, examination of public datasets revealed high levels of IL8 transcripts in HER2-enriched as well as basal-like primary breast tumors, two subtypes characterized by a particularly poor prognosis.
|
23062209 |
2012 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Modulation of genes related with invasion, metastasis and chemoresistance (ICAM-1, CXCL1, TNFAIP3, IL8) were confirmed in additional doxorubicin-treated cell lines and fresh primary human breast tumors.
|
24344116 |
2014 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Interleukin-8 (IL-8) is a pleiotropic chemokine involved in metastasis and angiogenesis of breast tumors.
|
25239884 |
2014 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Human Adipose-Derived Mesenchymal Stem Cell-Secreted CXCL1 and CXCL8 Facilitate Breast Tumor Growth By Promoting Angiogenesis.
|
28514506 |
2017 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In conjunction to metabolomic and degradome profiling, the use of NAF as liquid biopsy approach will improve the detection of changes in the cellular microenvironment of the breast tumors, understanding molecular and biochemical mechanisms which drive breast tumor initiation, maintenance and progression, and finally enhancing the development of novel drug targets and new treatment strategies.
|
28627779 |
2017 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our data suggest platelets support breast tumor metastasis by inducing tumor cells to secrete IL-8.
|
30670536 |
2019 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry was used to evaluate <i>VEGFA</i> and <i>MIF</i> levels in breast tumors and normal breast tissues; qPCRs and western blots were used to validate the expression of clinical immuno-oncology (IO) therapeutic targets <i>CD274</i> (<i>PD-L1</i>) and IL8 in cell lines.
|
31293831 |
2019 |